Punjab Chemicals & Crop Protection's (PCPL)
ambitious plans including overseas acquisitions
and a foray into the domestic agrochemical formulations
market could catapult it into an Indian MNC.
Its performance over the past three years has
been impressive. Top line grew at a CAGR of 36% and bottom line jumped at
a CAGR of 82%. The scrip is currently trading
at a P/E of just 6.51x FY06
EPS of Rs 25.34 and 5.44x FY08E EPS of
Rs 30.31. We rate the counter an OUT PERFORMER
with a price target of Rs 242 for an investment
horizon of 12-15 months.
Company Background
Punjab Chemicals & Crop Protection's (PCPL)
was incorporated in 1975 as a joint venture
between Excel Industries and Punjab State Industrial
Development Corporation. The company began by
producing oxalic acid and diethyl oxalate. It
regularly expanded capacities and soon became
a leading producer of both products. The company
got a major boost in the mid-1990s when it launched a high-value export-oriented herbicide. It
soon became a major producer of this product
worldwide. It further diversified into pharmaceuticals
when it acquired DSMs stake in Alpha Drugs
India (ADIL).
After going through a rough patch during 2000-02,
which culminated in a loss of Rs 1.85 crore,
the company has bounced back successfully. Top
line has grown at a CAGR of 36% and net profit
has improved at a CAGR of 82% over last three
years. It has managed this by introducing new
export oriented herbicides and expanding its
product range in chemicals by developing high
value intermediates mainly for the pharmaceutical
sector. The companys product portfolio has
also become well diversified and now consists
of agrochemicals, industrial chemicals &
intermediates and pharmaceuticals.
Sales Breakup
| Product |
Agrochemicals |
Industrial Chemicals & Intermediates |
Pharmaceuticals |
% Sales
|
58%
|
31%
|
11%
|
Investment Rationale
Global expansion via inorganic
route
The company plans to grow through the inorganic
route. It is planning to increase its portfolio
of registered products in high margin foreign
markets by acquiring companies in overseas markets.
This will also present an opportunity to shift
manufacturing to India that has a cost advantage.
The company proposes to fund these acquisitions
through a mix of debt and equity. It has already
convened an EGM and received shareholders approval
for raising Rs 400 crore through various instruments
like GDRs, FCCBs, private equity and structured
debt. It has also allotted 8.33 lakh preferential
convertible warrants to the promoters at Rs
231 per share aggregating to Rs 19.24 crore.
Consolidation of group
companies
The company has merged its group companies
STS Chemicals and Alpha Drugs with itself in
order to broad base its product portfolio and
also to benefit from the synergies of a consolidated
entity. It has established itself as a reliable
supplier and has contract manufacturing arrangements
with leading MNCs. Its clients include reputed
multinationals like Bayer, Dow, Ranbaxy Labs,
Nufarm, etc. With a well-diversified portfolio,
the company is now less sensitive to a downturn
in any single product category. The company
has developed a couple of new products for the
export market and is expected to launch them
in the third quarter of the current year.
Foray into local agro-chemical
formulations market
The company has recently acquired IA &
IC Chem, which has a state-of-the-art agro-chemical
formulation facility, giving it a footprint
in the domestic agro-chemical formulations market.
It has ambitious plans for the local market
and will be introducing new generation herbicides
and fungicides. This acquisition will also help
reduce transportation costs as well as ensure
faster delivery to its distributors since the
plant is located in Maharashtra.
Risks & Concerns
The companys plans are very ambitious compared to its current size and their success will depend on the managements ability to execute and integrate the acquisitions. Further, most of the funds for the acquisitions are yet to be tied up.
Sugar is a major raw material and sugar prices are currently on an upswing. Inability to pass price increases on to the customer would lead to EBIDTA margins shrinking.
| |
Quarter ended |
Year Ended |
Rs.cr |
Year |
|
2006 / 3 |
2005 / 3 |
var % |
|
2006 / 3 |
2005 / 3 |
|
var % |
| Sales
Income |
140.33 |
38.43 |
265.16 |
266.93 |
169.19 |
57.77 |
| Other
Income |
13.66 |
0.40 |
3,315.00 |
14.74 |
1.27 |
1,060.63 |
| Expenditure |
139.46 |
34.84 |
300.29 |
253.79 |
152.65 |
66.26 |
| Interest |
4.43 |
0.63 |
603.17 |
7.67 |
4.33 |
77.14 |
| Gross
Profit |
10.10 |
3.36 |
200.60 |
20.21 |
13.48 |
49.93 |
| Depreciation |
4.70 |
0.54 |
770.37 |
6.50 |
2.17 |
199.54 |
| Tax |
-3.42 |
0.63 |
-642.86 |
-0.27 |
3.99 |
-106.77 |
| PAT |
8.82 |
3.08 |
186.36 |
13.98 |
8.21 |
70.28 |
| Equity |
6.59 |
4.31 |
52.90 |
6.59 |
4.31 |
52.90 |
| OPM
(%) |
0.62 |
9.34 |
-8.72 |
4.92 |
9.78 |
-4.86 |
| GPM
(%) |
-2.54 |
7.70 |
-10.24 |
2.05 |
7.22 |
-5.17 |
| NPM
(%) |
6.28 |
8.01 |
-1.73 |
5.23 |
4.85 |
0.38 |
| Key Financial Ratios |
| |
2005 / 3 |
2004 / 3 |
2003 / 3 |
2002 / 3 |
2001 / 3 |
| EPS |
18.62 |
24.12 |
12.70 |
-14.17 |
2.77 |
| CEPS |
23.65 |
37.28 |
22.32 |
-5.29 |
11.70 |
| Book
Value |
71.79 |
113.83 |
95.35 |
85.47 |
112.89 |
| Dividend/Share |
4.00 |
5.00 |
2.50 |
0.00 |
1.25 |
| OPM |
10.18 |
9.80 |
8.27 |
1.97 |
6.87 |
| RONW |
28.77 |
20.09 |
13.71 |
-17.10 |
0.27 |
| Debt/Equity |
1.45 |
1.54 |
1.23 |
1.35 |
1.14 |
| Ratio |
2.08 |
2.03 |
1.72 |
2.35 |
3.29 |
| Interest
Cover |
4.08 |
3.91 |
3.70 |
0.47 |
1.59 |
|
Financials:
For FY06, PCPL reported a turnover of Rs 267 crore and net profit of Rs 16.7 crore, which works out to an EPS of Rs 25.34. It has healthy EBIDTA margin of 10.38% and net margins of 6.26%. The equity capital has gone up to Rs 6.59 crore subsequent to the three-way merger.
We expect FY08 revenues to grow to Rs 480 crore with an increase in net earnings to Rs 22.5 crore, resulting in EPS of Rs 30.31 on expanded equity capital of Rs 7.42 crore post-conversion of warrants issued to the promoters. These estimates are standalone and the consolidated figures post international acquisitions could be higher.
Valuations
The agro-chemical sector should continue to show strong growth since prices of agro commodities are in the midst of an ongoing global commodity boom. The benefits of the consolidation exercise will be visible from the current year and along with the international foray should lead to a re-rating of the stock. PCPL is available at 6.51x FY06 earnings and 5.44x FY08E earnings, which we feel is extremely attractive. The company has a consistent track record of dividend payment. For FY06, it has announced 40% dividend and the scrip is trading cum-dividend. At the current price, the dividend yield is 2.40%. We rate the stock an Outperformer with a price target of Rs 242 (8x FY08E EPS).
|